Cardiotoxicity of Doxorubicin and Other Anthracycline Derivatives

Overview

Journal J Nucl Cardiol

Specialty Cardiology & Vascular Diseases

Date 2000 Mar 4

PMID 10698235

Citations 34

Authors

D Jain

Affiliations

Soon will be listed here.

Citing Articles

Comprehensive Analysis of the Potential Toxicity of Magnetic Iron Oxide Nanoparticles for Medical Applications: Cellular Mechanisms and Systemic Effects.

Nowak-Jary J, Machnicka B Int J Mol Sci. 2024; 25(22).

PMID: 39596080 PMC: 11594039. DOI: 10.3390/ijms252212013.

In Vitro and Preclinical Antitumor Evaluation of Doxorubicin Liposomes Coated with a Cholesterol-Based Trimeric β-D-Glucopyranosyltriazole.

Maciel E Silva A, Maia A, Silva J, Miranda S, Cantini T, de Barros A Pharmaceutics. 2023; 15(12).

PMID: 38140092 PMC: 10747952. DOI: 10.3390/pharmaceutics15122751.

Engineering hairy cellulose nanocrystals for chemotherapy drug capture.

Young S, Muthami J, Pitcher M, Antovski P, Wamea P, Murphy R Mater Today Chem. 2022; 23.

PMID: 35224320 PMC: 8865441. DOI: 10.1016/j.mtchem.2021.100711.

Exercise Cardio-Oncology: Exercise as a Potential Therapeutic Modality in the Management of Anthracycline-Induced Cardiotoxicity.

Kang D, Wilson R, Christopher C, Normann A, Barnes O, Lesansee J Front Cardiovasc Med. 2022; 8:805735.

PMID: 35097024 PMC: 8796963. DOI: 10.3389/fcvm.2021.805735.

Genome-Wide DNA Methylation Signatures Predict the Early Asymptomatic Doxorubicin-Induced Cardiotoxicity in Breast Cancer.

Bauer M, Todorova V, Stone A, Carter W, Plotkin M, Hsu P Cancers (Basel). 2021; 13(24).

PMID: 34944912 PMC: 8699582. DOI: 10.3390/cancers13246291.

References

Gehl J, Boesgaard M, Paaske T, Jensen B, Dombernowsky P . Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol. 1996; 7(7):687-93. DOI: 10.1093/oxfordjournals.annonc.a010717. View

Goorin A, Chauvenet A, Perez-Atayde A, Cruz J, McKone R, Lipshultz S . Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer. J Pediatr. 1990; 116(1):144-7. DOI: 10.1016/s0022-3476(05)81668-3. View

Torti F, Bristow M, Lum B, Carter S, HOWES A, Aston D . Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res. 1986; 46(7):3722-7. View

Herman E, Zhang J, Hasinoff B, Clark Jr J, Ferrans V . Comparison of the structural changes induced by doxorubicin and mitoxantrone in the heart, kidney and intestine and characterization of the Fe(III)-mitoxantrone complex. J Mol Cell Cardiol. 1997; 29(9):2415-30. DOI: 10.1006/jmcc.1997.0477. View

Yamashita J, Ogawa M, Shirakusa T . Plasma endothelin-1 as a marker for doxorubicin cardiotoxicity. Int J Cancer. 1995; 62(5):542-7. DOI: 10.1002/ijc.2910620509. View

Schell F, Yap H, Blumenschein G, Valdivieso M, Bodey G . Potential cardiotoxicity with mitoxantrone. Cancer Treat Rep. 1982; 66(8):1641-3. View

GOLDENBERG M . Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther. 1999; 21(2):309-18. DOI: 10.1016/S0149-2918(00)88288-0. View

Young R, Ozols R, Myers C . The anthracycline antineoplastic drugs. N Engl J Med. 1981; 305(3):139-53. DOI: 10.1056/NEJM198107163050305. View

Estorch M, Carrio I, Berna L, Alonso C, Germa J, Ojeda B . Indium-111-antimyosin scintigraphy after doxorubicin therapy in patients with advanced breast cancer. J Nucl Med. 1990; 31(12):1965-9. View

10.

Black D, Livingston R . Antineoplastic drugs in 1990. A review (Part II). Drugs. 1990; 39(5):652-73. DOI: 10.2165/00003495-199039050-00003. View

11.

Schwartz R, McKenzie W, Alexander J, Sager P, Dsouza A, Manatunga A . Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med. 1987; 82(6):1109-18. DOI: 10.1016/0002-9343(87)90212-9. View

12.

Balazsovits J, Mayer L, Bally M, Cullis P, McDonell M, GINSBERG R . Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin. Cancer Chemother Pharmacol. 1989; 23(2):81-6. DOI: 10.1007/BF00273522. View

13.

Isner J, Ferrans V, Cohen S, Witkind B, Virmani R, Gottdiener J . Clinical and morphologic cardiac findings after anthracycline chemotherapy. Analysis of 64 patients studied at necropsy. Am J Cardiol. 1983; 51(7):1167-74. DOI: 10.1016/0002-9149(83)90364-8. View

14.

Jelic S, Radulovic S, Neskovic-Konstantinovic Z, Kreacic M, Ristovic Z, Bosnjak S . Cardioprotection with ICRF-187 (Cardioxane) in patients with advanced breast cancer having cardiac risk factors for doxorubicin cardiotoxicity, treated with the FDC regimen. Support Care Cancer. 1995; 3(3):176-82. DOI: 10.1007/BF00368887. View

15.

Bristow M, Mason J, Billingham M, Daniels J . Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Am Heart J. 1981; 102(4):709-18. DOI: 10.1016/0002-8703(81)90096-x. View

16.

Takano H, Ozawa H, Kobayashi I, Hamaoka S, Nakajima J, Nakamura T . Myocardial sympathetic dysinnervation in doxorubicin cardiomyopathy. J Cardiol. 1996; 27(2):49-55. View

17.

SUNG R, Huang G, Shing M, Oppenheimer S, Li C, Lau J . Echocardiographic evaluation of cardiac function in paediatric oncology patients treated with or without anthracycline. Int J Cardiol. 1997; 60(3):239-48. DOI: 10.1016/s0167-5273(97)00114-9. View

18.

Rahman A, More N, Schein P . Doxorubicin-induced chronic cardiotoxicity and its protection by liposomal administration. Cancer Res. 1982; 42(5):1817-25. View

19.

Pihkala J, Saarinen U, Lundstrom U, Virtanen K, Virkola K, Siimes M . Myocardial function in children and adolescents after therapy with anthracyclines and chest irradiation. Eur J Cancer. 1996; 32A(1):97-103. DOI: 10.1016/0959-8049(95)00555-2. View

20.

Carrio I, Lopez-Pousa A, Estorch M, Duncker D, Berna L, Torres G . Detection of doxorubicin cardiotoxicity in patients with sarcomas by indium-111-antimyosin monoclonal antibody studies. J Nucl Med. 1993; 34(9):1503-7. View